365 Days of Progress In Thoracic Oncology

16.9K

views

49

authors

6

articles

Editors

2

Lizza E.L. Hendriks

Maastricht University Medical Centre

New York University

Impact

About

“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.

This Research Topic aims to highlight the work featured and spark further discussion. The Thoracic Oncology field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.

We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.

The chosen manuscripts are :
- Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies

- Management of Large Cell Neuroendocrine Carcinoma

- First-Line Treatment Options for PD-L1–Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis

- KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

- Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities

- A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression

- Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis

- EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes

- The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.

This Research Topic aims to highlight the work featured and spark further discussion. The Thoracic Oncology field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.

We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.

The chosen manuscripts are :
- Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies

- Management of Large Cell Neuroendocrine Carcinoma

- First-Line Treatment Options for PD-L1–Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis

- KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

- Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities

- A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression

- Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis

- EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes

- The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

Share

Editors

Lizza E.L. Hendriks

Maastricht University Medical Centre

New York University

Impact

16,873 Total views

10,630 Article views

6,013 Article downloads

230 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

Thoracic Oncology

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic